BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35269787)

  • 1. Cytokine and Chemokine Receptor Patterns of Human Malignant Melanoma Cell Lines.
    Koroknai V; Szász I; Jámbor K; Balázs M
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene Expression Changes in Cytokine and Chemokine Receptors in Association with Melanoma Liver Metastasis.
    Koroknai V; Szász I; Balázs M
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of the mitogen-activated protein kinase pathway in malignant melanoma can occur independently of the BRAF T1799A mutation.
    Yazdi AS; Ghoreschi K; Sander CA; Röcken M
    Eur J Dermatol; 2010; 20(5):575-9. PubMed ID: 20605766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
    Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
    Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.
    Reifenberger J; Knobbe CB; Sterzinger AA; Blaschke B; Schulte KW; Ruzicka T; Reifenberger G
    Int J Cancer; 2004 Apr; 109(3):377-84. PubMed ID: 14961576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases.
    Birner P; Berghoff AS; Dinhof C; Pirker C; Capper D; Schoppmann SF; Petzelbauer P; von Deimling A; Berger W; Preusser M
    Arch Dermatol Res; 2014 Dec; 306(10):873-84. PubMed ID: 25073704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KIT Suppresses BRAF
    Neiswender JV; Kortum RL; Bourque C; Kasheta M; Zon LI; Morrison DK; Ceol CJ
    Cancer Res; 2017 Nov; 77(21):5820-5830. PubMed ID: 28947418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
    Lázár V
    Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abl kinase regulation by BRAF/ERK and cooperation with Akt in melanoma.
    Jain A; Tripathi R; Turpin CP; Wang C; Plattner R
    Oncogene; 2017 Aug; 36(32):4585-4596. PubMed ID: 28368422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of AID in malignant melanoma with BRAF(V600E) mutation.
    Okura R; Yoshioka H; Yoshioka M; Hiromasa K; Nishio D; Nakamura M
    Exp Dermatol; 2014 May; 23(5):347-8. PubMed ID: 24684646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas.
    Smalley KS; Lioni M; Dalla Palma M; Xiao M; Desai B; Egyhazi S; Hansson J; Wu H; King AJ; Van Belle P; Elder DE; Flaherty KT; Herlyn M; Nathanson KL
    Mol Cancer Ther; 2008 Sep; 7(9):2876-83. PubMed ID: 18790768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathological Characteristics of BRAF V600E Mutated Melanomas in the Dalmatian Region of Croatia.
    Bezić J; Kuret S; Vrbičić B; Smolić J; Borić I; Škifić I; Ledina D; Božić J
    Acta Dermatovenerol Croat; 2019 Dec; 27(4):225-230. PubMed ID: 31969234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma.
    Tap WD; Gong KW; Dering J; Tseng Y; Ginther C; Pauletti G; Glaspy JA; Essner R; Bollag G; Hirth P; Zhang C; Slamon DJ
    Neoplasia; 2010 Aug; 12(8):637-49. PubMed ID: 20689758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF(V600E) melanoma cells secrete factors that activate stromal fibroblasts and enhance tumourigenicity.
    Whipple CA; Brinckerhoff CE
    Br J Cancer; 2014 Oct; 111(8):1625-33. PubMed ID: 25117819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth suppression by dual BRAF(V600E) and NRAS(Q61) oncogene expression is mediated by SPRY4 in melanoma.
    Kumar R; Njauw CN; Reddy BY; Ji Z; Rajadurai A; Klebanov N; Tsao H
    Oncogene; 2019 May; 38(18):3504-3520. PubMed ID: 30651601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.
    Knight DA; Ngiow SF; Li M; Parmenter T; Mok S; Cass A; Haynes NM; Kinross K; Yagita H; Koya RC; Graeber TG; Ribas A; McArthur GA; Smyth MJ
    J Clin Invest; 2013 Mar; 123(3):1371-81. PubMed ID: 23454771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF
    Feng L; Li J; Bu X; Zuo Y; Shen L; Qu X
    Biochem Biophys Res Commun; 2020 Mar; 524(1):28-35. PubMed ID: 31980175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.
    Satzger I; Marks L; Kerick M; Klages S; Berking C; Herbst R; Völker B; Schacht V; Timmermann B; Gutzmer R
    Oncotarget; 2015 Nov; 6(35):37895-905. PubMed ID: 26498143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.
    Lázár V; Ecsedi S; Vízkeleti L; Rákosy Z; Boross G; Szappanos B; Bégány A; Emri G; Adány R; Balázs M
    Melanoma Res; 2012 Jun; 22(3):202-14. PubMed ID: 22456166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma.
    Kumar SM; Yu H; Edwards R; Chen L; Kazianis S; Brafford P; Acs G; Herlyn M; Xu X
    Cancer Res; 2007 Apr; 67(7):3177-84. PubMed ID: 17409425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.